Amendment: SEC Form S-1/A filed by CalAmp Corp.

IRVINE, Calif., March 13, 2025 (GLOBE NEWSWIRE) -- CalAmp (NASDAQ:CAMP), a global technology leader in telematics and fleet intelligence, is excited to announce its participation in the STN East Conference on March 24, 2025. The CalAmp Synovia team will be stationed at Booth 108, where they will connect with student transportation professionals and share insights on the latest trends shaping the industry. With over 1,000 school districts in the US and Canada relying on CalAmp's cutting-edge solutions, the company continues to lead the way in GPS tracking, fleet optimization, and student safety. Attendees visiting Booth 108 will have the opportunity to engage with friendly and knowledgeabl

CAMBRIDGE, Mass., Feb. 06, 2025 (GLOBE NEWSWIRE) -- CAMP4 Therapeutics Corporation ("CAMP4") (NASDAQ:CAMP), a clinical-stage biotechnology company developing a pipeline of regRNA-targeting antisense oligonucleotide (ASO) therapies to upregulate gene expression to restore healthy protein levels, today announced that Josh Mandel-Brehm, President & CEO, will participate in the following upcoming investor conferences: Oppenheimer's 35th Annual Healthcare Life Sciences ConferenceFormat:   Corporate PresentationDate and Time:  February 12, 2025, 10:00 a.m. ESTLocation:  VirtualWebcast Link:  Click Here    Leerink Partners Global Healthcare ConferenceFormat:  Fireside ChatDate and Time:  March 1

CAMBRIDGE, Mass., Jan. 13, 2025 (GLOBE NEWSWIRE) -- CAMP4 Therapeutics Corporation ("CAMP4") (NASDAQ:CAMP), a clinical-stage biotechnology company developing regRNA-targeting antisense oligonucleotide (ASO) therapies to upregulate gene expression to restore healthy protein levels, today announced that Josh Mandel-Brehm, President & CEO, will present a corporate update at the 43rd Annual J.P. Morgan Healthcare Conference taking place in San Francisco, California, on Wednesday, January 15, 2025, at 3:45 p.m. PST. The event will be webcast live and can be accessed on the investor relations page of CAMP4's website at www.investors.camp4tx.com. A replay of the webcast will be archived on the C

William Blair initiated coverage of CAMP4 Therapeutics with a rating of Outperform

Piper Sandler initiated coverage of CAMP4 Therapeutics with a rating of Overweight and set a new price target of $18.00

JP Morgan initiated coverage of CAMP4 Therapeutics with a rating of Overweight and set a new price target of $23.00

4/A - Camp4 Therapeutics Corp (0001736730) (Issuer)

4 - Camp4 Therapeutics Corp (0001736730) (Issuer)

4 - Camp4 Therapeutics Corp (0001736730) (Issuer)

4/A - Camp4 Therapeutics Corp (0001736730) (Issuer)

3/A - Camp4 Therapeutics Corp (0001736730) (Issuer)

4 - Camp4 Therapeutics Corp (0001736730) (Issuer)

8-K - Camp4 Therapeutics Corp (0001736730) (Filer)

10-Q - Camp4 Therapeutics Corp (0001736730) (Filer)

8-K - Camp4 Therapeutics Corp (0001736730) (Filer)

CAMBRIDGE, Mass., Dec. 10, 2024 (GLOBE NEWSWIRE) -- CAMP4 Therapeutics Corporation ("CAMP4") (NASDAQ:CAMP), a clinical-stage biotechnology company developing a pipeline of regRNA-targeting therapeutics designed to upregulate gene expression with the goal of restoring healthy protein levels across a range of genetic diseases, today announced the appointments of John Maraganore, Ph.D., and Rachel Meyers, Ph.D., as strategic advisors to the Company. For nearly 20 years, Dr. Maraganore served as the founding Chief Executive Officer and Director of Alnylam where he led the company's programs in RNA interference through global commercialization, resulting in the launch of the first four RNAi th

IRVINE, Calif., Jan. 08, 2024 (GLOBE NEWSWIRE) -- CalAmp (NASDAQ:CAMP), a connected intelligence company helping people and organizations improve operational performance with telematics solutions, is pleased to announce that Chris Adams will be joining the company as President and Chief Executive Officer (CEO), effective January 22, 2024. Adams is an accomplished technology leader who brings a wealth of knowledge and experience to CalAmp. He possesses a unique combination of technical depth, operational skills, and general management experience from a broad range of technology companies – most recently as VP/GM of the Automotive Sensing Division at onsemi. "After a comprehensiv

IRVINE, Calif., May 11, 2023 (GLOBE NEWSWIRE) -- CalAmp (NASDAQ:CAMP), a connected intelligence company helping people and organizations improve operational performance with a data-driven solutions ecosystem, today announced that Jeff Gardner will be stepping down from his role as Chief Executive Officer, effective no later than October 30, 2023. The Company has commenced a search for its next CEO and will be retaining an executive search firm. In announcing his departure, Jeff Gardner shared, "It has been a privilege working with the amazing group of colleagues at CalAmp. I am proud of all that we have accomplished and the progress we have made in positioning the Company for growth and p

IRVINE, Calif., Jan. 09, 2024 (GLOBE NEWSWIRE) -- CalAmp (NASDAQ:CAMP), a connected intelligence company that helps organizations monitor, track and protect their vital assets, today reported financial results for its third quarter of fiscal year 2024 ended November 30, 2023. Third Quarter Fiscal Year 2024 Financial Overview    Revenue was $53.6 million, representing a 13% decline QoQ and a 32% decline YoY driven primarily by softer demand in the TSP market segment.Gross margin was 33%, representing a decline of approximately 340 bps QoQ and 100 bps decline YoY as a result of a shift in product mix and a higher-than-normal reserve for excess and obsolete inventory.S&SS revenue was $34.5

IRVINE, Calif., Dec. 26, 2023 (GLOBE NEWSWIRE) -- CalAmp (NASDAQ:CAMP), a leading telematics solution provider that helps organizations improve operational performance, today announced that it will release its fiscal 2024 third quarter financial results after market close on Tuesday, January 9, 2024. In addition, the Company will host a conference call at 5:00 p.m. Eastern (2:00 p.m. Pacific) on January 9, 2024, to discuss its financial results. The call may be accessed via webcast by visiting the Investor Relations section of CalAmp's website at CalAmp IR Web Site. Please go to the website at least 15 minutes early to register, download and install any necessary audio software. A repla

IRVINE, Calif., Dec. 18, 2023 (GLOBE NEWSWIRE) -- CalAmp (NASDAQ:CAMP), a connected intelligence company helping people and organizations improve operational performance with telematics solutions, today announced the closing of a $45 million strategic financing with Lynrock Lake Master Fund LP ("Lynrock") in the form of a term loan maturing in November 2027. Lynrock is an existing holder of a large majority of CalAmp's 2.00% Convertible Senior Notes maturing in August 2025 (the "Notes"). In connection with the execution of the term loan agreement, CalAmp is amending the Notes to add a security interest. "As a long-standing investor in CalAmp, we are pleased to provide the company with add

SC 13G - Camp4 Therapeutics Corp (0001736730) (Subject)

SC 13D - Camp4 Therapeutics Corp (0001736730) (Subject)

SC 13G - Camp4 Therapeutics Corp (0001736730) (Subject)